SAN DIEGO and MARIETTA, Ga., Jan. 22, 2015 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of MiMedx Group, Inc. (NASDAQCM: MDXG) breached their fiduciary duties to shareholders. MiMedx designs, manufactures, and markets products and tissue processing services in the United States.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/mimedx-group-inc-jan-2015
MiMedx is the Focus of Multiple Federal Investigations
On September 4, 2013, various news outlets reported that on August 28, 2013, MiMedx had received a letter from the U.S. Food and Drug Administration citing that the company was not registered with the FDA to store and distribute its AmnioFix Injectable. On this news, MiMedx stock fell $2.21 per share, to close at $3.85 per share on September 4, 2013. More recently, on December 31, 2014, MiMedx announced that it received a subpoena from the Office of the Inspector General of the Department of Health and Human Services regarding an investigation into some of the company's sales and marketing activities, causing the company's stock to drop $1.79 per share, or 15%, to close at $9.74 on January 2, 2015.
MiMedx Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins Arroyo LLP